Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE 5 secukinumab in active psoriatic arthritis
NL-OMON42674Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriatic arthritis (PsA) (3 arms), sponsored by Novartis. Primary endpoint: ACR20 response at Week 24. Started Dec 2015; status: active, not recruiting.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON42674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42674.